Extended Data Fig. 1: Clinical activity of tumor response in patients with evaluable post-baseline tumor assessment per RECIST 1.1 by independent review committee. | Nature Medicine

Extended Data Fig. 1: Clinical activity of tumor response in patients with evaluable post-baseline tumor assessment per RECIST 1.1 by independent review committee.

From: Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Extended Data Fig. 1: Clinical activity of tumor response in patients with evaluable post-baseline tumor assessment per RECIST 1.1 by independent review committee.

a, Waterfall plot of tumor response in patients who received cemiplimab plus chemotherapy (n = 312). b, Waterfall plot of tumor response in patients who received placebo plus chemotherapy (n = 154). PD, progressive disease; SD, stable disease.

Back to article page